市場調查報告書
商品編碼
1422061
全球胃癌市場:按類型,階段,藥物類別,診斷,治療,給藥途徑,分銷管道,最終用戶,地區,機會,預測2017-2031Gastric Cancer Market Assessment, By Type, By Stages, By Drug Class, By Diagnosis, By Treatment, By Route of Administration, By Distribution Channel, By End-users, By Region, Opportunities and Forecast, 2017-2031F |
2023年全球胃癌市場規模將達48.7億美元。該市場預計到 2031 年將達到 128.3 億美元,並預計在 2024-2031 年預測期內複合年增長率為 12.88%。全球胃癌市場是一個與胃癌診斷、治療和研究相關的綜合市場。胃癌是一個嚴重的全球健康問題,造成重大的醫療、經濟和社會負擔。該市場涵蓋廣泛的活動,包括創新治療、診斷工具、支持性護理以及正在進行的臨床研究,以應對與這種疾病相關的挑戰。胃癌市場的進展主要集中在早期檢測技術、個人化治療選擇和改善患者預後。
診斷程序包括內視鏡檢查、影像技術和分子診斷測試,以在疾病的早期階段識別疾病並極大影響治療的成功率。隨著新療法的出現和尖端技術的整合,市場格局不斷發展。臨床試驗和研究計劃正在進行中,以探索創新療法,包括免疫療法、精準醫學和聯合療法。製藥公司、研究機構和醫療保健提供者之間的合作對於加深我們對胃癌的了解並開發更有效和有針對性的治療方法至關重要。此外,旨在提高認識、早期發現以及提供有關危險因素和症狀的教育的努力在全球胃癌整體管理中發揮著重要作用。不斷變化的胃癌市場模式強調了該領域持續研究、創新和合作的重要性,並有可能改善患者的治療結果。
近年來,在創新技術和治療方法的推動下,全球胃癌市場取得了顯著進展。一項值得注意的技術創新是精準醫療和標靶治療的出現,這些治療和標靶治療根據患者腫瘤的特定分子特徵為個別患者量身定制。檢查點抑制劑等免疫療法在某些情況下會透過增強人體對癌細胞的免疫反應而顯示出希望。此外,包括機器人輔助手術在內的微創手術技術的進步改善了治療效果,減少了患者的不適並縮短了康復時間。
隨著用於胃癌早期檢測和監測的液體活檢的發展,診斷工具也在不斷發展。這些測試提供了一種侵入性較小的方法來分析循環腫瘤 DNA,有可能實現更快的干預和個人化治療策略。例如,2023年1月,Eisai Co., Ltd.在加州舊金山舉行的2023年美國臨床腫瘤學會(ASCO)胃腸道癌症研討會(#GI23)上召開了關於各種胃腸道癌症類型的會議。會介紹我們的研究。
本報告調查了全球胃癌市場,並提供了市場概況,以及按類型、階段、藥物類別、診斷、治療、給藥途徑、分銷渠道、最終用戶、地區和進入該市場的公司概況劃分的趨勢。市場。
Global gastric cancer market size was valued at USD 4.87 billion in 2023, which is expected to reach USD 12.83 billion in 2031, growing with a CAGR of 12.88% for the forecast period between 2024 and 2031F. The global gastric cancer market pertains to a comprehensive landscape involving the diagnosis, treatment, and research dedicated to gastric (stomach) cancer. Gastric cancer is a significant health concern worldwide, it poses a considerable medical, economic, and social burden. The market encompasses a broad spectrum of activities, including innovative therapies, diagnostic tools, supportive care, and ongoing clinical research to address the challenges associated with the disease. Advancements in the gastric cancer market primarily focus on early detection techniques, personalized treatment options, and improving patient outcomes.
Diagnostic procedures involve endoscopic examinations, imaging technologies, and molecular diagnostic tests to identify the disease at its initial stages, significantly impacting treatment success rates. The market's landscape is continually evolving due to the emergence of novel therapeutic approaches and the integration of cutting-edge technologies. Clinical trials and research initiatives are ongoing, exploring innovative treatment options, including immunotherapies, precision medicines, and combination therapies. Collaboration between pharmaceutical companies, research institutions, and healthcare providers is critical for advancing the understanding of gastric cancer and developing more effective and targeted therapies. Additionally, initiatives aimed at raising awareness, early detection, and providing education about risk factors and symptoms play a crucial role in the overall management of gastric cancer on a global scale. The evolving landscape of gastric cancer market holds promise for improved patient outcomes, emphasizing the importance of continued research, innovation, and collaboration in the field.
The global gastric cancer market has seen significant advancements in recent years, driven by innovative technologies and treatment approaches. One notable innovation involves the emergence of precision medicine and targeted therapies tailored to individual patients based on specific molecular characteristics of their tumors. Immunotherapies, such as checkpoint inhibitors, have shown promise in some cases by enhancing the body's immune response against cancer cells. Additionally, advancements in minimally invasive surgical techniques, including robotic-assisted surgery, have improved treatment outcomes, reducing patient discomfort and recovery times.
Diagnostic tools too have evolved, with the development of liquid biopsies for early detection and monitoring of gastric cancer. These tests offer a less invasive method to analyze circulating tumor DNA, potentially allowing for quicker intervention and personalized treatment strategies. For instance, in January 2023, Eisai Co., Ltd. announced the showcasing of their research covering diverse gastrointestinal cancer types at the 2023 American Society of Clinical Oncology (ASCO) symposium on gastrointestinal cancers (#GI23), held in San Francisco, California.
The Global Gastric Cancer Market product approvals are increasing due to the complex nature of these diseases. The increase in product approvals, collaboration, and innovation are pivotal. Research institutions, pharmaceutical companies, and regulatory bodies are collaborating closely to streamline clinical trials and expedite the approval process. Furthermore, investing in technological advancements like precision medicine and immunotherapy significantly enhances treatment outcomes, leading to more successful drug approvals.
For instance, in March 2023, Akeso, Inc., finalized the enrolment of patients for its crucial Phase III clinical trial for cadonilimab (AK104), a groundbreaking PD-1/CTLA-4 bi-specific antibody. The achievement represents a significant milestone as it is the first dual-immune checkpoint bi-specific antibody drug to receive approval and enter the market. The advancement brings cadonilimab one step closer to its official launch for a major indication following the successful approval for the treatment of cervical cancer.
A strategic partnership between key players in global gastric cancer market holds significant promise for advancing the diagnosis, treatment, and overall management of the prevalent malignancy. Such collaborations can leverage the combined expertise and resources of pharmaceutical companies, research institutions, and healthcare providers to address the multifaceted challenges gastric cancer poses. These partnerships can accelerate the development of innovative therapies, diagnostic tools, and treatment protocols, ultimately improving patient outcomes. By pooling their knowledge and capabilities, stakeholders can better understand gastric cancer molecular underpinnings and optimize clinical trial designs, potentially leading to more effective and targeted treatments. Additionally, partnerships can facilitate early detection and screening programs, thereby increasing the chances of early intervention, and reducing the global burden of gastric cancer.
For instance, during February 2022, Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb entered a contract with Prime Research Institute for Medical RWD, Inc. This agreement aimed to conduct extensive, industry-sponsored, multi-institutional clinical research involving patients with gastric cancer. The study focused on the treatment involving Opdivo in conjunction with chemotherapy.
Precision medicine in the global gastric cancer market has significantly advanced, leveraging individual patient variability in genes, environment, and lifestyle for tailored treatment. Innovations like next-generation sequencing, biomarker identification, and molecular profiling have revolutionized diagnosis and therapy selection. Targeted therapies, like trastuzumab for HER2-positive tumors, exemplify precision medicine's impact by improving patient outcomes. Companion diagnostics enables patients to respond to specific treatments, optimizing efficacy, and reducing adverse effects. The integration of big data analytics and artificial intelligence further refines treatment strategies, predicting responses and disease progression.
However, challenges such as cost, accessibility, and data interpretation persist, hindering widespread implementation. For instance, according to an article published in July 2022 in PubMed, the progress of precision medicine has continuously received substantial support from the remarkable strides achieved in both local and global studies concerning molecular targeted therapy for gastric cancer in recent years.
The global healthcare systems were widely impacted by the COVID-19 pandemic, significantly influencing the market for gastric cancer therapy. The diagnosis and treatment of gastric cancer experienced delays or cancellations owing to the worldwide lockdown measures. For example, a March 2023 article in PubMed highlighted how during the initial period of the pandemic, the care of gastric cancer patients worldwide suffered due to reduced multidisciplinary team meetings and a decline in elective gastrectomy. Amid the COVID-19 pandemic, delays in diagnosing and treating cancer placed patients at risk of negative consequences. These delays significantly affected the market's growth due to treatment and diagnosis disruptions. Nevertheless, the market for gastric cancer treatments has now reverted to its pre-pandemic state.
The competitive landscape of global gastric cancer market offers comprehensive insights on competitors. These details include company profiles, financial standings, revenue generation, market opportunities, research and development investments, new market strategies, international reach, manufacturing facilities, production capabilities, strengths and weaknesses, product launches, product diversity, and dominant applications. It is important to note that the mentioned data points specifically pertain to the companies' involvement in the global gastric cancer market.
BDR Pharma announced the introduction of Furmecil (recognized as S-1), a composite of three medications-Tegafur, Gimeracil, and Oteracil, in April 2022. Oral medication is specified for treating advanced gastric cancer in adults. According to a statement from BDR Pharma, Furmecil has displayed notable efficacy and a positive safety profile in its use.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.